Kevin Tang

Kevin Tang is recorded as Board Member at Aurinia Pharmaceuticals Inc. (AUPH) since May 15, 2025 and CEO at Aurinia Pharmaceuticals Inc. (AUPH). The newest filing on record that lists Kevin Tang as CEO at Aurinia Pharmaceuticals Inc. (AUPH) is dated April 21, 2026. Earlier roles on record: Board Member at Heron Therapeutics, Inc. (HRTX) until August 4, 2020. Aurinia Pharmaceuticals Inc. reported in an 8-K filed March 23, 2026 that Kevin Tang was appointed Chief Executive Officer, effective March 23, 2026. Aurinia Pharmaceuticals Inc. reported in an 8-K filed May 15, 2025 that Kevin Tang was appointed members of the Company's board of directors, effective May 15, 2025. Aurinia Pharmaceuticals Inc. reported in an 8-K filed September 12, 2024 that Kevin Tang was appointed Director. Equibles holds 4 filed executive changes naming Kevin Tang; each is listed under recent activity with its source filing. Aurinia Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aurinia Pharmaceuticals Inc. includes Jeffrey Bailey (CEO and Board Member), Peter Greenleaf (CEO and Board Member), Joseph Miller (CFO) and 7 others.